The stem cells of acute myeloid leukemia (AML) are the malignancy initiating cells whose survival ultimately drives growth of these lethal diseases. Here we review leukemia stem cell (LSC) biology, particularly as it relates to the very heterogeneous nature of AML and to its high disease relapse rate. Leukemia ontogeny is presented, and the defining functional and phenotypic features of LSCs are explored. Surface and metabolic phenotypes of these cells are described, particularly those that allow distinction from features of normal hematopoietic stem cells (HSCs). Opportunities for use of this information for improving therapy for this challenging group of diseases is highlighted, and we explore the clinical needs which may be addressed by emerging LSC data. Finally, we discuss current gaps in the scientific understanding of LSCs.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Estey, E. H. (2018). “Acute myeloid leukemia: 2019 update on risk-stratification and management,” (in eng). American Journal of Hematology, 93(10), 1267–1291. https://doi.org/10.1002/ajh.25214
Bonnet, D., & Dick, J. E. (1997). “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” (in eng). Nature Medicine, 3(7), 730–737. https://doi.org/10.1038/nm0797-730
Sanchez-Aguilera, A., & Mendez-Ferrer, S. (2017). The hematopoietic stem-cell niche in health and leukemia. Cellular and Molecular Life Sciences, 74(4), 579–590. https://doi.org/10.1007/s00018-016-2306-y
Batsivari, A., Grey, W., & Bonnet, D. (2021). Understanding of the crosstalk between normal residual hematopoietic stem cells and the leukemic niche in acute myeloid leukemia. Experimental Hematology, 95, 23–30. https://doi.org/10.1016/j.exphem.2021.01.004
Fialkow, P. J. (1979). Clonal origin of human tumors. Annual Review of Medicine, 30, 135–143. https://doi.org/10.1146/annurev.me.30.020179.001031
R. G. Wiggans, Jacobson, R. J., Fialkow, P. J., Woolley, 3rd P. V. , Macdonald, J. S., & Schein, P. S. (1978). Probable clonal origin of acute myeloblastic leukemia following radiation and chemotherapy of colon cancer,. Blood, 52(4), 659–663. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/278630.
Lapidot, T., et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645–648.
Kreso, A., & Dick, J. E. (2014). “Evolution of the cancer stem cell model,” (in eng). Cell Stem Cell, 14(3), 275–291. https://doi.org/10.1016/j.stem.2014.02.006
Nowell, P. C., & Hungerford, D. A. (1964). Chromosome changes in human leukemia and a tentative assessment of their significance. Annals of the New York Academy of Sciences, 113, 654–662. https://doi.org/10.1111/j.1749-6632.1964.tb40697.x
Mitelman, F., Nilsson, P. G., Levan, G., & Brandt, L. (1976). Non-random chromosome changes in acute myeloid leukemia. Chromosome banding examination of 30 cases at diagnosis. International Journal of Cancer, 18(1), 31–38. https://doi.org/10.1002/ijc.2910180106
Arber, D. A., et al. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391–2405. https://doi.org/10.1182/blood-2016-03-643544
Papaemmanuil, E., Dohner, H., & Campbell, P. J. (2016). Genomic Classification in Acute Myeloid Leukemia. New England Journal of Medicine, 375(9), 900–901. https://doi.org/10.1056/NEJMc1608739
Dohner, H., et al. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129(4), 424–447. https://doi.org/10.1182/blood-2016-08-733196
Stubbs, M. C., et al. (2008). MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: Development of a model for rapid therapeutic assessment. Leukemia, 22(1), 66–77. https://doi.org/10.1038/sj.leu.2404951
Uckelmann, H. J., et al. (2020). Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science, 367(6477), 586–590. https://doi.org/10.1126/science.aax5863
Song, C., et al. (2016). Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia. Leukemia, 30(6), 1436–1440. https://doi.org/10.1038/leu.2015.331
N. Cancer Genome Atlas Research et al. (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England Journal of Medicine, 368(22), 2059–2074. https://doi.org/10.1056/NEJMoa1301689.
Wang, J. C., & Dick, J. E. (2005). “Cancer stem cells: Lessons from leukemia,” (in eng). Trends in Cell Biology, 15(9), 494–501. https://doi.org/10.1016/j.tcb.2005.07.004
Majeti, R., Park, C. Y., & Weissman, I. L. (2007). “Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood,” (in eng). Cell Stem Cell, 1(6), 635–645. https://doi.org/10.1016/j.stem.2007.10.001
Blair, A., Hogge, D. E., Ailles, L. E., Lansdorp, P. M., & Sutherland, H. J. (1997). “Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo,” (in eng). Blood, 89(9), 3104–3112.
Miyamoto, T., Weissman, I. L., & Akashi, K. (2000). “AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation,” (in eng). Proc Natl Acad Sci U S A, 97(13), 7521–7526. https://doi.org/10.1073/pnas.97.13.7521
Shlush, L. I., et al. (2014). “Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia,” (in eng). Nature, 506(7488), 328–333. https://doi.org/10.1038/nature13038
Busque, L., et al. (2012). Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics, 44(11), 1179–1181. https://doi.org/10.1038/ng.2413
Genovese, G., et al. (2014). Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. New England Journal of Medicine, 371(26), 2477–2487. https://doi.org/10.1056/NEJMoa1409405
Genovese, G., Jaiswal, S., Ebert, B. L., & McCarroll, S. A. (2015). Clonal hematopoiesis and blood-cancer risk. New England Journal of Medicine, 372(11), 1071–1072. https://doi.org/10.1056/NEJMc1500684
Kwok, B., et al. (2015). MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood, 126(21), 2355–2361. https://doi.org/10.1182/blood-2015-08-667063
Buscarlet, M., et al. (2017). DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood, 130(6), 753–762. https://doi.org/10.1182/blood-2017-04-777029
Jaiswal, S., et al. (2014). Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine, 371(26), 2488–2498. https://doi.org/10.1056/NEJMoa1408617
Loberg, M. A., et al. (2019). Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis. Leukemia, 33(7), 1635–1649. https://doi.org/10.1038/s41375-018-0368-6
Chen, J., et al. (2019). Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nature Medicine, 25(1), 103–110. https://doi.org/10.1038/s41591-018-0267-4
Cleary, A. S., Leonard, T. L., Gestl, S. A., & Gunther, E. J. (2014). Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature, 508(7494), 113–117. https://doi.org/10.1038/nature13187
Kleppe, M., & Levine, R. L. (2014). Tumor heterogeneity confounds and illuminates: Assessing the implications. Nature Medicine, 20(4), 342–344. https://doi.org/10.1038/nm.3522
Miles, L. A., et al. (2020). Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature, 587(7834), 477–482. https://doi.org/10.1038/s41586-020-2864-x
Lapidot, T., et al. (1994). “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” (in eng). Nature, 367(6464), 645–648. https://doi.org/10.1038/367645a0
Ishikawa, F., et al. (2005). “Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain(null) mice,” (in eng). Blood, 106(5), 1565–1573. https://doi.org/10.1182/blood-2005-02-0516
Barve, A., Casson, L., Krem, M., Wunderlich, M., Mulloy, J. C., & Beverly, L. J. (2018). Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response. Experimental Hematology, 67, 18–31. https://doi.org/10.1016/j.exphem.2018.08.004
Taussig, D. C., et al. (2008). “Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells,” (in eng). Blood, 112(3), 568–575. https://doi.org/10.1182/blood-2007-10-118331
Hope, K. J., Jin, L., & Dick, J. E. (2004). “Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity,” (in eng). Nature Immunology, 5(7), 738–743. https://doi.org/10.1038/ni1080
Thomas, D., & Majeti, R. (2017). “Biology and relevance of human acute myeloid leukemia stem cells,” (in eng). Blood, 129(12), 1577–1585. https://doi.org/10.1182/blood-2016-10-696054
Ishikawa, F., et al. (2007). “Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region,” (in eng). Nature Biotechnology, 25(11), 1315–1321. https://doi.org/10.1038/nbt1350
Saito, Y., et al. (2010). “Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML,” (in eng). Nature Biotechnology, 28(3), 275–280. https://doi.org/10.1038/nbt.1607
Boyd, A. L., et al. (2018). “Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of Human AML Recurrence,” (in eng). Cancer Cell, 34(3), 483-498.e5. https://doi.org/10.1016/j.ccell.2018.08.007
Farge, T., et al. (2017). “Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism,” (in eng). Cancer Discovery, 7(7), 716–735. https://doi.org/10.1158/2159-8290.cd-16-0441
Griessinger, E., et al. (2014). “A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: A new tool to decipher their chemoresistance and self-renewal mechanisms,” (in eng). Stem Cells Translational Medicine, 3(4), 520–529. https://doi.org/10.5966/sctm.2013-0166
Iwasaki, M., Liedtke, M., Gentles, A. J., & Cleary, M. L. (2015). “CD93 marks a non-quiescent human leukemia stem cell population and is required for development of MLL-rearranged acute myeloid leukemia,” (in eng). Cell Stem Cell, 17(4), 412–421. https://doi.org/10.1016/j.stem.2015.08.008
Gebru, M. T., et al. (2020). Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia. Blood, 136(9), 1067–1079. https://doi.org/10.1182/blood.2019003124
Touzet, L., et al. (2019). “CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells,” (in eng). Cancer Medicine, 8(3), 1279–1288. https://doi.org/10.1002/cam4.2007
Saito, Y., et al. (2010). “Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells," (in eng). Sci Transl Med, 2(17), 17ra9. https://doi.org/10.1126/scitranslmed.3000349
Riether, C., et al. (2017). “CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia,” (in eng). Journal of Experimental Medicine, 214(2), 359–380. https://doi.org/10.1084/jem.20152008
Taussig, D. C., et al. (2005). “Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia,” (in eng). Blood, 106(13), 4086–4092. https://doi.org/10.1182/blood-2005-03-1072
Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F., & Dick, J. E. (2006). “Targeting of CD44 eradicates human acute myeloid leukemic stem cells,” (in eng). Nature Medicine, 12(10), 1167–1174. https://doi.org/10.1038/nm1483
Kersten, B., et al. (2016). “CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia,” (in eng). British Journal of Haematology, 173(2), 219–235. https://doi.org/10.1111/bjh.13941
Goardon, N., et al. (2011). “Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia,” (in eng). Cancer Cell, 19(1), 138–152. https://doi.org/10.1016/j.ccr.2010.12.012
Majeti, R., et al. (2009). “CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells,” (in eng). Cell, 138(2), 286–299. https://doi.org/10.1016/j.cell.2009.05.045
Oehler, V. G., et al. (2010). CD52 expression in leukemic stem/progenitor cells. Blood, 116(21), 2743. https://doi.org/10.1182/blood.V116.21.2743.2743
de Boer, B., et al. (2018). “Prospective isolation and characterization of genetically and functionally distinct AML subclones,” (in eng). Cancer Cell, 34(4), 674-689.e8. https://doi.org/10.1016/j.ccell.2018.08.014
Hosen, N., et al. (2007). “CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia,” (in eng). Proc Natl Acad Sci U S A, 104(26), 11008–11013. https://doi.org/10.1073/pnas.0704271104
Chung, S. S. et al. (2017). "CD99 is a therapeutic target on disease stem cells in myeloid malignancies," (in eng). Science Translational Medicine, 9(374). https://doi.org/10.1126/scitranslmed.aaj2025.
Jordan, C. T., et al. (2000). “The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells,” (in eng). Leukemia, 14(10), 1777–1784. https://doi.org/10.1038/sj.leu.2401903
Ho, J. M., et al. (2020). “CD200 expression marks leukemia stem cells in human AML,” (in eng). Blood Advances, 4(21), 5402–5413. https://doi.org/10.1182/bloodadvances.2020001802
Jan, M., et al. (2011). “Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker,” (in eng). Proc Natl Acad Sci U S A, 108(12), 5009–5014. https://doi.org/10.1073/pnas.1100551108
Kikushige, Y., et al. (2010). “TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells,” (in eng). Cell Stem Cell, 7(6), 708–717. https://doi.org/10.1016/j.stem.2010.11.014
van Rhenen, A., et al. (2007). “The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells,” (in eng). Blood, 110(7), 2659–2666. https://doi.org/10.1182/blood-2007-03-083048
Pabst, C., et al. (2016). “GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo,” (in eng). Blood, 127(16), 2018–2027. https://doi.org/10.1182/blood-2015-11-683649
Barreyro, L., et al. (2012). “Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS,” (in eng). Blood, 120(6), 1290–1298. https://doi.org/10.1182/blood-2012-01-404699
Ågerstam, H., et al. (2015). “Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia,” (in eng). Proc Natl Acad Sci U S A, 112(34), 10786–10791. https://doi.org/10.1073/pnas.1422749112
Askmyr, M., et al. (2013). “Selective killing of candidate AML stem cells by antibody targeting of IL1RAP,” (in eng). Blood, 121(18), 3709–3713. https://doi.org/10.1182/blood-2012-09-458935
Eppert, K., et al. (2011). “Stem cell gene expression programs influence clinical outcome in human leukemia,” (in eng). Nature Medicine, 17(9), 1086–1093. https://doi.org/10.1038/nm.2415
Hogan, C. J., Shpall, E. J., & Keller, G. (2002). “Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice,” (in eng). Proc Natl Acad Sci U S A, 99(1), 413–418. https://doi.org/10.1073/pnas.012336799
Bakker, A. B., et al. (2004). “C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia,” (in eng). Cancer Research, 64(22), 8443–8450. https://doi.org/10.1158/0008-5472.can-04-1659
Zeijlemaker, W., et al. (2019). CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia, 33(5), 1102–1112. https://doi.org/10.1038/s41375-018-0326-3
Falini, B., et al. (2005). Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.[see comment][erratum appears in N Engl J Med. 2005 Feb 17;352(7):740]. New England Journal of Medicine, 352(3), 254–266.
Warburg, O. (1956). “On the origin of cancer cells,” (in eng). Science, 123(3191), 309–314. https://doi.org/10.1126/science.123.3191.309
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033. https://doi.org/10.1126/science.1160809
Elstrom, R. L., et al. (2004). “Akt stimulates aerobic glycolysis in cancer cells,” (in eng). Cancer Research, 64(11), 3892–3899. https://doi.org/10.1158/0008-5472.can-03-2904
Gottschalk, S., Anderson, N., Hainz, C., Eckhardt, S. G., & Serkova, N. J. (2004). “Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells,” (in eng). Clinical Cancer Research, 10(19), 6661–6668. https://doi.org/10.1158/1078-0432.ccr-04-0039
Ye, H., et al. (2018). “Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells,” (in eng). Cancer Cell, 34(4), 659-673.e6. https://doi.org/10.1016/j.ccell.2018.08.016
Kobayashi, C. I., & Suda, T. (2012). “Regulation of reactive oxygen species in stem cells and cancer stem cells,” (in eng). Journal of Cellular Physiology, 227(2), 421–430. https://doi.org/10.1002/jcp.22764
Janiszewska, M., et al. (2012). “Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells,” (in eng). Genes & Development, 26(17), 1926–1944. https://doi.org/10.1101/gad.188292.112
Lagadinou, E. D., et al. (2013). “BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells,” (in eng). Cell Stem Cell, 12(3), 329–341. https://doi.org/10.1016/j.stem.2012.12.013
Diehn, M., et al. (2009). “Association of reactive oxygen species levels and radioresistance in cancer stem cells,” (in eng). Nature, 458(7239), 780–783. https://doi.org/10.1038/nature07733
Chen, Z. X., & Pervaiz, S. (2007). “Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells,” (in eng). Cell Death and Differentiation, 14(9), 1617–1627. https://doi.org/10.1038/sj.cdd.4402165
DiNardo, C. D., et al. (2018). Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: A non-randomised, open-label, phase 1b study. The lancet Oncology, 19(2), 216–228. https://doi.org/10.1016/S1470-2045(18)30010-X
Pollyea, D. A., et al. (2018). Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nature Medicine, 24(12), 1859–1866. https://doi.org/10.1038/s41591-018-0233-1
DiNardo, C. D., et al. (2018). “Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies,” (in eng). American Journal of Hematology, 93(3), 401–407. https://doi.org/10.1002/ajh.25000
Jones, C. L., et al. (2018). “Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells,” (in eng). Cancer Cell, 34(5), 724-740.e4. https://doi.org/10.1016/j.ccell.2018.10.005
Jones, C. L., et al. (2020). “Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells,” (in eng). Cell Stem Cell, 27(5), 748-764.e4. https://doi.org/10.1016/j.stem.2020.07.021
Hilton, J. (1984). Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Research, 44(11), 5156–60. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/6488175.
Tsukamoto, N., Chen, J., & Yoshida, A. (1998). Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Blood Cells, Molecules, & Diseases, 24(2), 231–238. https://doi.org/10.1006/bcmd.1998.0188
Corti, S., et al. (2006). Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells, 24(4), 975–985. https://doi.org/10.1634/stemcells.2005-0217
Ma, S., et al. (2008). Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Molecular Cancer Research, 6(7), 1146–1153. https://doi.org/10.1158/1541-7786.MCR-08-0035
Morimoto, K., et al. (2009). Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Science, 100(6), 1062–1068. https://doi.org/10.1111/j.1349-7006.2009.01151.x
Jiang, F., et al. (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Molecular Cancer Research, 7(3), 330–338. https://doi.org/10.1158/1541-7786.MCR-08-0393
Cheung, A. M., et al. (2007). Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia, 21(7), 1423–1430. https://doi.org/10.1038/sj.leu.2404721
Schuurhuis, G. J., et al. (2013). Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS ONE, 8(11), e78897. https://doi.org/10.1371/journal.pone.0078897
Hoang, V. T., et al. (2015). The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients. International Journal of Cancer, 137(3), 525–536. https://doi.org/10.1002/ijc.29410
Smith, C., Gasparetto, M., Humphries, K., Pollyea, D. A., Vasiliou, V., & Jordan, C. T. (2014). “Aldehyde dehydrogenases in acute myeloid leukemia,” (in eng). Annals of the New York Academy of Sciences, 1310, 58–68. https://doi.org/10.1111/nyas.12414
Venton, G., et al. (2016). “Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors,” (in eng). Blood Cancer J, 6(9), e469. https://doi.org/10.1038/bcj.2016.78
Annageldiyev, C., et al. (2019). The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia. Haematologica, 13, 485. https://doi.org/10.3324/haematol.2018.212886
Broccoli, D., Young, J. W., & De Lange, T. (1995). Telomerase activity in normal and malignant hematopoietic cells. Proceedings of the National academy of Sciences of the United States of America, 92, 9082–9086.
Watts, J. M., et al. (2016). Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. Leukemia Research, 49, 62–65. https://doi.org/10.1016/j.leukres.2016.07.013
Williams, J., et al. (2017). Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology, 178(2), 240–249. https://doi.org/10.1111/bjh.14666
Lansdorp, P. M. (2017). Maintenance of telomere length in AML. Blood Advances, 1(25), 2467–2472. https://doi.org/10.1182/bloodadvances.2017012112
Ly, M., et al. (2019). Diminished AHR signaling drives human acute myeloid leukemia stem cell maintenance. Cancer Research, 79(22), 5799–5811. https://doi.org/10.1158/0008-5472.CAN-19-0274
Pabst, C., et al. (2014). Identification of small molecules that support human leukemia stem cell activity ex vivo. Nature Methods, 11(4), 436–442. https://doi.org/10.1038/nmeth.2847
Walter, R. B., et al. (2014). Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. Leukemia, 28(10), 1969–1977. https://doi.org/10.1038/leu.2014.107
Ng, S. W., et al. (2016). A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature, 540(7633), 433–437. https://doi.org/10.1038/nature20598
Pinho, S., & Frenette, P. S. (2019). Haematopoietic stem cell activity and interactions with the niche. Nature Reviews Molecular Cell Biology, 20(5), 303–320. https://doi.org/10.1038/s41580-019-0103-9
Villatoro, A., Konieczny, J., Cuminetti, V., & Arranz, L. (2020). Leukemia stem cell release from the stem cell niche to treat acute myeloid leukemia. Front Cell Dev Biol, 8, 607. https://doi.org/10.3389/fcell.2020.00607
Nervi, B., et al. (2009). Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood, 113(24), 6206–6214. https://doi.org/10.1182/blood-2008-06-162123
Sievers, E. L., et al. (2001). Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19(13), 3244–3254.
Hauswirth, A. W., et al. (2007). Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. European Journal of Clinical Investigation, 37(1), 73–82.
Wadleigh, M., et al. (2003). Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.[see comment]. Blood, 102(5), 1578–1582.
Petersdorf, S. H., et al. (2013). “A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia,” (in eng). Blood, 121(24), 4854–4860. https://doi.org/10.1182/blood-2013-01-466706
Kim, M. Y., et al. (2018). “Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia,” (in eng). Cell, 173(6), 1439-1453.e19. https://doi.org/10.1016/j.cell.2018.05.013
Jin, L., et al. (2009). “Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells,” (in eng). Cell Stem Cell, 5(1), 31–42. https://doi.org/10.1016/j.stem.2009.04.018
Kubasch, A. S., et al. (2020). Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia, 34(4), 1182–1186.
Montesinos, P., et al. (2021). “Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: Results from a multicenter, randomized, phase 2/3 study,” (in eng). Leukemia, 35(1), 62–74. https://doi.org/10.1038/s41375-020-0773-5
Liu, J., et al. (2015). “Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential,” (in eng). PLoS ONE, 10(9), e0137345. https://doi.org/10.1371/journal.pone.0137345
Pang, W. W., et al. (2013). “Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes,” (in eng). Proc Natl Acad Sci U S A, 110(8), 3011–3016. https://doi.org/10.1073/pnas.1222861110
Chao, M. P., et al. (2019). “Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies,” (in eng). Frontiers in Oncology, 9, 1380. https://doi.org/10.3389/fonc.2019.01380
Aslostovar, L., et al. (2018). “A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia,” (in eng). Blood Advances, 2(15), 1935–1945. https://doi.org/10.1182/bloodadvances.2018015677
Yanagisawa, B., et al. (2020). Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. Leukemia Research, 99, 106477. https://doi.org/10.1016/j.leukres.2020.106477
Amatangelo, M. D., et al. (2017). Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood, 130(6), 732–741. https://doi.org/10.1182/blood-2017-04-779447
Popovici-Muller, J., et al. (2018). Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Medicinal Chemistry Letters, 9(4), 300–305. https://doi.org/10.1021/acsmedchemlett.7b00421
This work is supported by the NIH award 2P01CA171983-06A1 and funds from the Kenneth Noel Memorial Foundation – to Dr. Claxton.
Consent to Participate
Consent for Publication
The authors give their consent.
Conflict of Interest
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Long, N.A., Golla, U., Sharma, A. et al. Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications. Stem Cell Rev and Rep 18, 1211–1226 (2022). https://doi.org/10.1007/s12015-021-10308-6
- Leukemia Stem Cell
- Acute Myeloid Leukemia